Articles tagged with Prostate Cancer
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
A new study found that prostate cancer overdiagnosis increases with age, with low rates in younger men and high rates in older men. The study suggests that targeted PSA testing or screening policies for men in their 50s and early 60s may be more effective.
New research suggests that federal housing assistance may lead to better two-year survival chances among older men with prostate cancer. The study found a 12% lower risk of death in men who received housing assistance compared to those without it.
Research finds PDX1 gene plays a tumor-promoting role in human PCa cells by influencing metabolic pathways. The study identifies PDX1 as differentially hypermethylated in prostate cancer tissues, contributing to its aggressive characteristics.
A new randomized clinical trial found that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with MRI-guided, transurethral ultrasound ablation (TULSA) compared to robotic prostate surgery. TULSA resulted in less blood loss, shorter hospital s...
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.
Six Weill Cornell Medicine researchers have been awarded Young Investigator Awards by the Prostate Cancer Foundation to investigate prostate cancer at a molecular level and develop new therapies. Drs. Bashir Al Hussein Al Awamlh, Cheuk Man Cherie Au, Lise Brault, Xuanrong Chen, Kevin Kensler, and Silvia Rodrigues will focus on improvin...
A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.
A large clinical trial led by UCL researchers has shown that hormone patches are as effective as injections in controlling locally advanced prostate cancer. The patches cause fewer side effects, including hot flushes and breast tissue swelling, while improving quality of life for men with the condition.
Scientists have identified a new cell type and discovered that many normal-looking prostate cells harbor cancer-related changes. The study's findings could lead to new risk factors, earlier detection methods, and more targeted therapies for patients at high risk of aggressive disease.
A study found CREB5 regulates basal and SCL transcriptional programs and tumor-forming phenotypes in prostate cancer, suggesting a central role in aggressive prostate cancer. Disrupting CREB5-regulated pathways may improve therapeutic responses in advanced disease.
UCLA researchers identified a key protein, E2F3, essential for survival in cancer cells lacking the protective gene RB. Blocking E2F3 effectively halted tumor growth, offering a new strategy for treating aggressive cancers.
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
A study by the University of Texas M. D. Anderson Cancer Center found that men with low testosterone levels are 60% more likely to have their prostate cancer progress to a more aggressive state during surveillance. Low testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
A new study has discovered microplastics in nine out of ten patients with prostate cancer, with higher levels found in tumor tissue than noncancerous tissue. The findings suggest that microplastic exposure may be a risk factor for prostate cancer.
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
Researchers found patients who retreated with docetaxel had longer overall survival and fewer supportive-care needs compared to those switching to cabazitaxel. The study provides evidence-based options for selected patients previously tolerated docetaxel.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Men who took oxybutynin also reported improvements in day-to-day functioning and overall quality of life.
Researchers identified a gene expression signature and inflammation patterns in normal tissue near the tumor to distinguish between patients with aggressive disease. The study paves the way for early identification of high-risk patients through blood or semen samples.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A new study reveals the CDK12-FOXA1-MDM2-p53 signaling axis promotes prostate cancer development through FOXA1 modification. The study identifies S234 phosphorylation as a critical site, and a CDK12 inhibitor THZ531 effectively blocks this pathway, reducing tumor growth.
A new AI-powered analysis tool called PROVIZ is being tested in Norwegian hospitals to diagnose prostate cancer. The tool helps doctors determine which patients need a biopsy, reducing the number of unnecessary procedures.
A meta-analysis of individual patients with oligometastatic prostate cancer shows that metastasis-directed radiation therapy (MDT) significantly improves patient outcomes, including delayed disease progression and better quality of life. The study included 574 men and found a median of 7.6 months before disease progression in the MDT a...
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
A review decodes the comprehensive role of GDF15 in prostate cancer metabolism, chemoresistance, and clinical applications, highlighting its involvement in cachexia, bone metastasis, and drug resistance. The study also explores the synergistic power of combining GDF15 with established markers for improved diagnosis and prognosis.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
A phase 2 clinical trial is comparing three strategies to protect heart health in prostate cancer patients undergoing hormone therapy. The study will assess the impact of intermittent fasting, GLP-1 medication, and nutritional counseling on cardiovascular and metabolic risks associated with androgen deprivation therapy.
Researchers summarize the role of metabolic reprogramming in driving prostate cancer progression, highlighting key regulators and inter-pathway crosstalk mechanisms. Novel targeted therapeutic strategies targeting glucose, glutamine, and lipid metabolism are proposed to overcome current treatment bottlenecks.
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
Researchers at VCU Massey Comprehensive Cancer Center and VCU Institute of Molecular Medicine are developing a novel therapy using engineered immune cells to target advanced prostate cancer. The therapy, which uses genetically modified natural killer cells producing the IL-24S 'Superkine', has shown promise in early-stage studies.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.